Trevi Therapeutics Inc TRVI

NAS: TRVI | ISIN: US89532M1018 29/04/2024

2,940 USD (+5,76%)

(+5,76%) 29/04/2024

Grafiek Trevi Therapeutics Inc

Grafiek Trevi Therapeutics Inc

1 dag1d 5,76%
1 week1w 3,16%
1 maand1m -12,50%
3 maanden3m 93,42%
6 maanden6m 60,66%
1 jaar1j -11,84%
5 jaar5j -62,74%

Trevi Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

9 april 2024 · Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference · Persbericht

4 april 2024 · Trevi Therapeutics to Participate in Upcoming April Events · Persbericht

2 april 2024 · Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team · Persbericht

20 maart 2024 · Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates · Persbericht

13 maart 2024 · Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024 · Persbericht

28 februari 2024 · Trevi Therapeutics to Participate in Upcoming March Events · Persbericht

6 februari 2024 · Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference · Persbericht

4 januari 2024 · Trevi Therapeutics Provides Business Updates · Persbericht

5 december 2023 · Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) · Persbericht

9 november 2023 · Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update · Persbericht

Profiel Trevi Therapeutics Inc

Gezondheidstechnologie

Medicinale en botanische productie

Werknemers: 26

Aandelen Trevi Therapeutics Inc

Beurswaarde: 191,71 miljoen USD

Effecten: 68,96 miljoen

Beta: 0,50

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe